Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 24, 2018

Primary Completion Date

June 16, 2023

Study Completion Date

December 30, 2025

Conditions

Carcinoma of Unknown Primary

Interventions

DRUG

Pembrolizumab Injection

Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.

Trial Locations (3)

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

Ottawa Hospital Cancer Centre, Ottawa

All Listed Sponsors

collaborator

Tom Baker Cancer Centre

OTHER

lead

AHS Cancer Control Alberta

OTHER

NCT03391973 - Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) | Biotech Hunter | Biotech Hunter